Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart defects may complicate recovery for childhood cancer survivors

NCT ID NCT07249138

Knowledge-focused Sponsor: Children's Hospital of Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 800 children who survived blood cancer to see if having a congenital heart defect raises their risk of death or other health problems later in life. Researchers also checked for shared genetic links between the two conditions. The goal is to better understand and care for these survivors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict and manage long-term health problems in childhood cancer survivors who also have heart defects.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to all survivors, and the findings might not lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

800 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will comprise pediatric patients with hematological malignancies who also have congenital heart disease, identified through a multi-center collaborative network spanning major tertiary hospitals across China. This cohort will include children aged 0-18 years at diagnosis who were treated between 2010 and 2025, with detailed clinical data collected retrospectively from participating medical institutions. The selection specifically focuses on patients who completed standard oncologic treatment and received confirmed congenital heart disease diagnoses through comprehensive cardiac evaluation.

Ages

0 weeks to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Children with hematologic malignancies diagnosed by pathology or bone marrow aspiration/biopsy at member hospitals of the Hematologic Oncology Specialty Alliance between 2010 and 2025; 2. Aged 0-17 years at diagnosis, regardless of gender; 3. Completed standard treatment for hematologic malignancies and confirmed diagnosis of congenital heart disease by cardiac ultrasound and clinical evaluation; 4. Written informed consent can be provided by the child or their legal guardian. Exclusion Criteria: 1. Presence of birth defects other than congenital heart disease; 2. Other serious cardiac conditions, malignancies, or comorbidities that may interfere with study results; 3. Inability to provide the information and data required for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital heart disease (CHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital heart disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital heart disease (CHD) Hematologic malignancy

Contacts and locations

Locations

  • Beijing Children's Hospital

    Beijing, China

  • Children's Hospital of Fudan University

    Shanghai, China

  • Children's Hospital of Soochow University

    Suzhou, China

  • Guangzhou Women and Children's Medical Center

    Guangzhou, China

  • Inner Mongolia Maternal and Child Health Care Hospital

    Hohhot, China

  • Nanjing Children's Hospital

    Nanjing, China

  • Northwest Women's and Children's Hospital

    Xi'an, China

  • Shandong Provincial Hospital

    Jinan, China

  • Shanghai Children's HospitalShanghai Children's Hospital

    Shanghai, China

  • Shanxi Children's Hospital

    Taiyuan, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Tongji Hospital of Huazhong University of Science and Technology

    Wuhan, China

  • Union Hospital of Huazhong University of Science and Technology

    Wuhan, China

  • Wuhan Children's Hospital

    Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.